First booster of SARS-COV-2 mRNA vaccine is not associated with alloimmunization and subclinical injury of kidney allograft

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00083763" target="_blank" >RIV/00023001:_____/23:00083763 - isvavai.cz</a>

Result on the web

<a href="https://journals.lww.com/transplantjournal/Fulltext/2023/02000/First_Booster_of_SARS_COV_2_mRNA_Vaccine_Is_Not.40.aspx" target="_blank" >https://journals.lww.com/transplantjournal/Fulltext/2023/02000/First_Booster_of_SARS_COV_2_mRNA_Vaccine_Is_Not.40.aspx</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/TP.0000000000004421" target="_blank" >10.1097/TP.0000000000004421</a>

Result language

angličtina

Original language name

First booster of SARS-COV-2 mRNA vaccine is not associated with alloimmunization and subclinical injury of kidney allograft

Original language description

Background: Booster doses of mRNA SARS-CoV-2 vaccines have been widely administered to kidney transplant recipients (KTRs). However, there is a scarcity of safety data as KTRs have been excluded from vaccine clinical trials. The objective of this prospective, observational study is the evaluation of the safety of the first booster dose of mRNA vaccine in 108 virus-naive KTRs.Methods: Samples were obtained on the day of booster vaccination and subsequently three months later. Anti-HLA antibodies, donor-derived cell-free DNA (dd-cfDNA), clinical adverse events, and SARS-CoV-2 IgG antibodies were evaluated.Results: We detected no significant safety signals in KTRs after the booster dose. De novo donor-specific (DSA) anti-HLA antibody was detected in just a single case. There was no increase in anti-HLA antibodies mean fluorescence intensity (MFI), immunodominant antibodies MFI or calculated panel-reactive antibodies following the booster (p&gt;0.9 for all tests, respectively). A principal component analysis on anti-HLA antibodies showed a significant overlap between the two measurements and no differential clustering, PERMANOVA analysis revealed no significant differences between the two measurements (p&gt;0.999). There was no significant increase of dd-cfDNA above the 1% threshold in any KTR and, similarly, there was no overall increase in dd-cfDNA levels following the booster (p=0.427). There were no differences in eGFR before and after the booster, and no graft rejection was observed following vaccination. After the third dose, seroconversion was found in 80.6% KTRs.Conclusions: The first booster dose of mRNA SARS-CoV-2 vaccine is not associated with an increased risk of alloreactivity and sub/clinical kidney allograft injury (NCT05483725).

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30217 - Urology and nephrology

Project

<a href="/en/project/NU22-C-126" target="_blank" >NU22-C-126: Aspects of immune response and efficacy of booster dose of SARS-CoV-2 mRNA vaccine in kidney transplant recipients</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Transplantation

ISSN

0041-1337

e-ISSN

1534-6080

Volume of the periodical

107

Issue of the periodical within the volume

2

Country of publishing house

US - UNITED STATES

Number of pages

3

Pages from-to

"e62"-"e64"

UT code for WoS article

000923643000005

EID of the result in the Scopus database

2-s2.0-85147047106